Losartan Potassium Tablet, Film Coated
Product Images NDC 51655-795

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 51655-795). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 795 26 Master Bottle Label Approval Rev A 01 22)

This is a description of a 90-tablet bottle of Losartan Potassium tablets, USP, each of which contains 50mg of the active ingredient. The NDC code is 51655-795-26 and it is repackaged by Northwind Pharmaceuticals in Indianapolis. The LCN# is 00 and the Rev. A01/22. The tablets should be stored at room temperature, between 20°C and 25°C, with permitted excursions to between 15°C and 30°C. The expiry date is given as 00/00/0000 and the lot number is 0000000000. The package insert and dosage information are not provided.*

FDA Label Image

Figure1 (Losartan Fig1)

This appears to be a graph or chart with labels for two different medications, Atenolol and Losartan Potassium. It also includes a measure of "Adjusted Risk Reduction" and a progression of months (6-66). Without further context or the ability to view the graph/chart, it is difficult to provide a more specific description or interpretation.*

FDA Label Image

Figure2 (Losartan Fig2)

This appears to be a chart or table showing the percentage of patients experiencing fatal or non-fatal stroke while taking Atenolol or Losartan Potassium over a 66-month study period. No further information or context is provided, so it is difficult to interpret the results or make recommendations based on the data presented.*

FDA Label Image

Figure 3 (Losartan Fig3)

The provided text is a table or figure containing data on the primary endpoint events for different demographic subgroups. The subgroups are identified by age, gender, race, and history of VD. The table shows the number or percentage of events for each subgroup compared to the overall results. There are also some unclear or unrecognizable characters and phrases in the text.*

FDA Label Image

Figure-4 (Losartan Fig4)

This appears to be a table displaying the percentage of patients with an event for two different treatments, Losttan Potassium and placebo. The table also shows a risk reduction of 16.1% and a p-value of 0.022. Without further context, it is not clear what event is being referred to or what study this table is taken from.*

FDA Label Image

Chemical Structure (Losartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.